These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37401187)

  • 1. Prostate-specific membrane antigen positron emission tomography detected local failure after post-prostatectomy radiation therapy: Low rates of out-of-field recurrence validates current Australian prostate bed contouring guidelines.
    Shakespeare TP; Yap SZL; Hsieh M; Tahir ARM; Armstrong S
    J Med Imaging Radiat Oncol; 2023 Sep; 67(6):662-667. PubMed ID: 37401187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes.
    Horsley PJ; Koo CM; Eade T; Hsiao E; Emmett L; Brown C; Kneebone A; Hruby G
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):106-117. PubMed ID: 35716849
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Sonni I; Dal Pra A; O'Connell DP; Ells Z; Benz M; Nguyen K; Yoon SM; Deng J; Smith C; Grogan T; Nickols NG; Cao M; Kishan AU; Calais J
    J Nucl Med; 2023 Jun; 64(6):902-909. PubMed ID: 36759200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMA-PET-guided dose-escalated volumetric arc therapy for newly diagnosed lymph node-positive prostate cancer: 5 Year outcomes following the FROGG and EviQ node-positive guidelines.
    Yap SZL; Armstrong S; Aherne N; Shakespeare TP
    J Med Imaging Radiat Oncol; 2023 Jun; 67(4):456-462. PubMed ID: 37186452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Based Clinical Target Volume Delineation Guideline for Postprostatectomy Salvage Radiation Therapy: The PERYTON Guideline.
    Staal FHE; Janssen J; Oprea-Lager DE; Engelen AM; van Limbergen EJ; Smeenk RJ; de Jong MAA; Budiharto TCG; Jacobs I; Haverkort DMAD; Brouwer CL; Ng Wei Siang K; Langendijk JA; Verzijlbergen JF; de Jong IJ; Noordzij W; Aluwini S
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):688-696. PubMed ID: 37729971
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-defining
    Tissot S; Wynn J; Tran V; Farag M; Wong LM; Ng M
    BJU Int; 2023 Oct; 132(4):411-419. PubMed ID: 37216190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial.
    Harmon G; Chan D; Lee B; Miller C; Gorbonos A; Gupta G; Quek M; Woods M; Savir-Baruch B; Harkenrider MM; Solanki AA
    Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):1195-1203. PubMed ID: 34015368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
    Boreta L; Gadzinski AJ; Wu SY; Xu M; Greene K; Quanstrom K; Nguyen HG; Carroll PR; Hope TA; Feng FY
    Urology; 2019 Jul; 129():165-171. PubMed ID: 30928607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of
    Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
    Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.
    Schiller K; Stöhrer L; Düsberg M; Borm K; Devecka M; Vogel MME; Tauber R; Heck MM; Rauscher I; Eiber M; Gschwend JE; Duma MN; Combs SE
    Eur Urol Oncol; 2021 Feb; 4(1):73-83. PubMed ID: 32451312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
    BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation.
    Imber BS; O'Dwyer E; Lobaugh S; McBride SM; Hopkins M; Kollmeier M; Gorovets D; Brennan V; Pike LRG; Gewanter R; Mychalczak B; Zhang Z; Schöder H; Zelefsky MJ
    Urology; 2022 Dec; 170():146-153. PubMed ID: 36115426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of
    Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
    Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
    World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
    Staal FHE; Janssen J; Brouwer CL; Langendijk JA; Ng Wei Siang K; Schuit E; de Jong IJ; Verzijlbergen JF; Smeenk RJ; Aluwini S
    BMC Cancer; 2022 Apr; 22(1):416. PubMed ID: 35428210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.